Cholecalciferol Supplementation for Anemia and Mineral and Bone Disorder in Hemodialysis Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-08-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether cholecalciferol supplementation decrease the blood concentrations of hepcidin-25 in hemodialysis patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effects of Cholecalciferol on Osteoprotegerin Levels in Patients on Peritoneal Dialysis

NCT02598635

Vitamin D Deficiency Vascular Calcification Renal Insufficiency +1 more

UNKNOWN PHASE4

Vitamin D Effect on Calcium Absorption on Persons on Hemodialysis

NCT01325610

Chronic Kidney Disease End Stage Renal Disease Vitamin D Deficiency

COMPLETED NA

Cholecalciferol Supplementation in Hemodialysis Patients

NCT05922696

Anemia Hemodialysis Complication Vitamin D Deficiency

COMPLETED PHASE2/PHASE3

Hemodialysis Vitamin D Pilot

NCT01214928

Vitamin D Deficiency Renal Failure Chronic Requiring Hemodialysis

COMPLETED NA

Vitamin D Supplement Study for Stage Three and Four Chronic Kidney Disease (CKD) Patients

NCT01173848

Chronic Kidney Disease Stage 3 and 4

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

There are 4 arms in this study: (1) Thrice-weekly cholecalciferol supplementation (3,000 IU), (2) Monthly cholecalciferol supplementation (equivalent to 9,000/week), (3) Thrice-weekly placebo, and (4) Monthly placebo. The primary analyses will be done regarding 2 cholecalciferol groups and 2 placebo groups as one group each, and we will evaluate the effect of cholecalciferol regardless of the supplementation regimen. As the secondary analyses, we will examine if there is any difference between thrice-weekly and once-monthly supplementation regimen.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kidney Failure, Chronic Anemia Vitamin D Deficiency Bone Diseases, Metabolic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Thrice-weekly cholecalciferol

Capsule containing 3,000 IU of cholecalciferol will be given at the end of each hemodialysis session. Dissolved with olive oil and coated by soft capsule made of gelatin and glycerin.

Group Type ACTIVE_COMPARATOR